Matt Ocko is co-Managing Partner and co-founder of Data Collective (DCVC), a venture capital firm that backs innovative entrepreneurs building deep compute, big data, and IT infrastructure companies able to transform huge markets, including life sciences, traditional industry, and agriculture. DCVC’s portfolio includes Zymergen (where Matt serves on the board), Nervana (INTC), Pivot Bio, Atomwise, Vium, Freenome, Transcriptic, Agenovir, Vicarious, 3Scan, Cofactor Genomics, Molecular Stethoscope, SequenceBio, and Citrine.io. Matt has three decades of experience as a technology entrepreneur and VC, in the US and globally. In addition to large IPO outcomes, many of Matt’s prior investments were acquired to become core capabilities of companies like Illumina, Cisco, Google, IBM, Amazon, and Akamai. He was also an early investor in Facebook (FB), Uber, and AngelList. Matt’s current investments on behalf of DCVC range across next-generation bioinformatics, genomics, and synthetic biology, as well as robotics and AI to accelerate discoveries in these fields. Matt holds a degree in Physics from Yale University, and he is an inventor on over 40 granted or in-process patents in areas ranging from computer systems virtualization to fraud detection. He has been active on a pro-bono basis in helping develop China’s venture capital and technology regulatory framework for two decades.